- The second P-III SAkuraStar study involves assessing of Satralizumab (120 mg) as monothx. vs PBO in97 patients in a ratio (2:1) with AQP4-IgG seropositive or seronegative NMO and AQP4-IgG seropositive NMOSD aged 20-70yrs.
- The P-III SAkuraStar study results: 55% & 74% reduction in risk of relapse in overall population & AQP4-IgG seropositive patients; relapse free patients in overall population @48 & 96wks. (76.1% & 72.1% vs 61.9% & 51.2%), in AQP4-IgG seropositive (82.9% & 76.5% vs 55.4% & 41.1%) respectively
- Satralizumab is mAb targeting IL-6 receptor being evaluated in two P-III studies SAkuraStar and SAkuraSky as monothx. & in combination with baseline therapy for NMSOD respectively
Click here to read full press release/ article | Ref: Roche | Image: Deviant Art